Compare Prudential PLC (PUK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Recursion Pharmaceuticals Inc — how do they compare? Prudential PLC trades at $24.03 (market cap $28.84B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Prudential PLC is far larger — about 13.5× Recursion Pharmaceuticals Inc's market cap, and Prudential PLC pays a 2.33% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PUK | RXRX | |
|---|---|---|
Market Cap | $28.84B | $2.14B |
Volume | 3,531,298 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $33.61 | $6.79 |
52-Week Low | $23.54 | $2.84 |
Typical Hold Time | 119 Days | 22 Days |
Enterprise Value | $28.38B | $1.66B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.54, down 4.31% today, amid bearish technical signals. The company shows strong fundamentals with revenue growth from $16.2B in 2024 to $27.4B in 2025 and net income of $4.0B. Valuation ratios appear attractive with P/E of 8.28 and P/S of 1.01. Recent news highlights strategic shifts including emerging-market exits and a $3B capital rotation plan. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook balances solid profitability and growth against technical weakness and macroeconomic risks. Investment appeal lies in undervalued metrics and strategic refocusing, but near-term price pressure and execution risks on new initiatives warrant caution. The stock offers value for long-term investors if the company delivers on its five-year strategic targets.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
